Akebia Therapeutics (AKBA) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $49.1M
- Gross margin
- 79.63%
- Net income (quarter)
- −$8.9M
- Net income growth (year over year)
- −3706.48%
- Net margin
- −13.54%
- Return on equity
- −109.38%
- Book value per share
- $0.09
- Price to book
- 7.78
- Debt to assets
- 92.85%
Company profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Frequently asked questions
Is Akebia Therapeutics (AKBA) profitable?
No. Akebia Therapeutics reported a net loss of $29.7M over the trailing twelve months.
How much revenue does Akebia Therapeutics (AKBA) make?
Akebia Therapeutics generated $219.1M in revenue over the trailing twelve months, down 21.36% year over year.
How do I buy stock in Akebia Therapeutics (AKBA)?
AKBA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.